Abstract:BackgroundCardio-protective effect of fibrate therapy is controversial and current research is to evaluate the effect of fenofibrate therapy on rats with hypertriglycemia.MethodsRats with hypertriglycemia were produced by 10% fructose administration (10 ml daily) for 4 weeks. After model has been successfully produced as reflected by increased triglyceride level, different doses of fenofibrate, namely low dose (50 mg/kg body weight) and high dose (100 mg/kg body weight), were orally prescribed for 2 weeks. At baseline, 4 weeks of fructose administration and 2 weeks of fenofibrate therapy, parameters of interest were evaluated and compared.ResultsAt baseline, no significant differences of parameter were observed between groups. After 4 weeks of fructose prescription, triglyceride level increased in company with high density lipoprotein cholesterol (HDL-C) and apoprotein A1 (ApoA1) decreased. C-reactive protein (CRP) and malondialdehyde (MDA) levels were also elevated. Endothelial function was impaired as reflected by reduced nitric oxide (NO) production and elevated serum asymmetric dimethylarginine (ADMA) level. All these changes were significant as compared to the control group (P < 0.05), suggesting that short-term of triglyceride elevation could potently initiate atherosclerosis. With 2 weeks of fenofibrate therapy, in comparison to un-treated group, triglyceride level was significantly reduced in parallel with HDL-C and ApoA1 elevation. Inflammation and oxidation were also profoundly ameliorated as reflected by CRP and MDA reduction. Notably, NO production was enhanced in company with serum ADMA level decrease. Overall, these improvements manifested in a dose-dependent manner, which was supported by multivariate regression analysis showing that after adjusted to other variables, the dose of fenofibrate therapy remained significantly associated with NO production and serum ADMA level, with OR of 1.042 (high-dose versus low-dose, 95% CI 1.028-1.055, P < 0.05).ConclusionsFenofibrate therapy not only could reduce triglyceride level but also confer pleiotropic effects in terms of endothelium-protection and amelioration of inflammation and oxidation in a dose-dependent manner.

Effects of Fenofibrate on the Expressions of PPAR-γ,LXR Α and ABCA1 Mrna in Rats Model with Hyperlipaemia

PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats]

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Upregulation of Hepatic VLDLR Via PPARα is Required for the Triglyceride-Lowering Effect of Fenofibrate.

Effect of Fenofibrate on Adiponectin Gene Expression and Endothelial Function in Diabetic Rats

Effects and mechanism of simvastatin and fenofibrate on the expression of hepatic apolipoprotein M in mice

Fenofibrate Improves Vascular Endothelial Function and Contractility in Diabetic Mice

Pleiotropic effects of fenofibrate therapy on rats with hypertriglycemia

Fenofibrate Ameliorates Insulin Resistance in Lipoprotein Lipase Heterozygous Knockout Mice and Its Possible Mechanisms

Fenofibrate Reduces Serum Retinol-Binding Protein-4 by Suppressing Its Expression in Adipose Tissue

Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease

Effects of fenofibrate and pioglitazone on expressions of intracellular signaling molecules in pancreatic islet of high-fat diet-fed rats

[The effect of fenofibrate on expression of genes involved in fatty acids beta-oxidation and associated free-radical processes]

Study on the Mechanism of Fenofibrate-Inhibited Expression of Plasminogen Activator Inhibitor-1 in Adipose Tissue from Cholesterol-Fed Rabbits

Effect of Fenofibrate on the Expression of Uncoupling Protein 3 Gene in Skeletal Muscle of Diabetic Rats Fed with High Fat Diet

Modulation Effect of Peroxisome Proliferator-Activated Receptor Agonists on Lipid Droplet Proteins in Liver

Fenofibrate Enhances Cd36 Mediated Endocytic Uptake and Degradation of Oxidized Low Density Lipoprotein in Adipocytes from Hypercholesterolemia Rabbit

Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-α

Effect of Fenofibrate on LDL-induced Endothelial Dysfunction in Rats

Fenofibrate Inhibits Thrombogenic and Fibrinolytic Factors Expression in Adipose Tissue of Atherosclerotic Rabbits.

Role of fenofibrate in activation of farnesoid X receptor transcriptional activity